Industry / Switzerland

Innovative Drugs Drive Market

March 2008 | Industry News

Printable version
Email
Bookmark

BMI has revised its forecasts for the Swiss drug market after new figures were released by IMS Health. We now expect drug spending to reach US$5.56bn in 2012, representing a compound annual growth rate (CAGR) of 4.6%.

To read the full article, please sign in or take a free trial.

Related Insight Articles

BfArM Approves Generic Plavix

Companies / Switzerland Germany's main regulatory body, the Federal Institute for Drugs and Medical Devices (BfArM), has controversially approved a generic form of global blockbuster Plavix (clopidogrel). The generic form of...

May 2008

Novartis And Bayer To Go Head To Head Following EU Extavia Approval

Industry / Switzerland Swiss drugmaker Novartis has obtained EU approval for its multiple sclerosis (MS) treatment Extavia (interferon beta-1b), which will result in a head-to-head battle with Bayer's identical competitor...

May 2008

Novartis Further Diversifies With Investment In Alcon

Companies / Switzerland Swiss pharmaceutical giant Novartis is set to acquire an US$11bn stake in the ophthalmic group Alcon from Nestlé. Novartis has announced that it will acquire 25% of Alcon for US$143.18 per share. The...

April 2008

Innovative Drugs Drive Market

Industry / Switzerland BMI has revised its forecasts for the Swiss drug market after new figures were released by IMS Health. We now expect drug spending to reach US$5.56bn in 2012, representing a compound annual growth rate...

March 2008

Focus On Medical Devices

Industry / Switzerland Switzerland's medical device market is highly developed and was worth approximately US$4.1bn in 2007. By 2012 the market should reach a value of US$5.2bn, representing a compound annual growth rate (CAGR)...

March 2008